Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.33 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.33 |
| ▸ | DPYD | Q12882 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9453387 | 0.73 | KDM4E (0.35) | MCL1KDM4EHPGD | |
| SCHEMBL10728222 | 0.69 | DAO (0.42) | DAOKDM4EHPGDUPP1 | |
| SCHEMBL845977 | 0.68 | KDM5A (0.35) | KDM5AKDM5CKDM5BMCL1UPP1 | |
| SCHEMBL19712290 | 0.66 | KDM4E (0.33) | KDM5AKDM5CKDM5BKDM4EHPGD | |
| SCHEMBL13906254 | 0.64 | MCL1 (0.44) | DAOKDM5AKDM5CKDM5BMCL1 | |
| SCHEMBL1573448 | 0.64 | MEN1 (0.50) | KDM4EHPGD | |
| SCHEMBL29842862 | 0.64 | MEN1 (0.50) | KDM4EHPGD | |
| SCHEMBL12974187 | 0.63 | HTT (0.40) | ADRA1AMCL1KDM4E | |
| SCHEMBL27564163 | 0.63 | ALDH1A1 (0.41) | ADRA1AMCL1KDM4EHPGD | |
| SCHEMBL9670330 | 0.62 | DAO (0.35) | ADRA1ADAOHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130823-A1 | PROCESS FOR THE PRODUCTION OF ANTITUMOUR PHARMACEUTICAL COMPOSITIONS USING PUSH-PULL BUTADIENES, COMPOUNDS AND USES THEREOF | ANHANGUERA EDUCACIONAL PARTICIPAÇÕES S/A (BR) | 2023-04-27 | — | — | US | disclosed |
| US-20230130823-A1 | PROCESS FOR THE PRODUCTION OF ANTITUMOUR PHARMACEUTICAL COMPOSITIONS USING PUSH-PULL BUTADIENES, COMPOUNDS AND USES THEREOF | ANHANGUERA EDUCACIONAL PARTICIPAÇÕES S/A (BR) | 2023-04-27 | — | — | US | disclosed |
| WO-2021077194-A1 | PROCESS FOR THE PRODUCTION OF ANTITUMOUR PHARMACEUTICAL COMPOSITIONS USING PUSH-PULL BUTADIENES, COMPOUNDS AND USES THEREOF | ANHANGUERA EDUCACIONAL PARTICIPAÇÕES S/A (BR) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130823-A1 | PROCESS FOR THE PRODUCTION OF ANTITUMOUR PHARMACEUTICAL COMPOSITIONS USING PUSH-PULL BUTADIENES, COMPOUNDS AND USES THEREOF | BAD, BAX, PDCD4 | ADRA1A 2788/4885DAO 4001/4885KDM5A 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.